China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Sees Significant Growth in Short Interest

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) saw a significant increase in short interest in the month of June. As of June 15th, there was short interest totaling 71,896 shares, an increase of 1,295.8% from the May 31st total of 5,151 shares. Based on an average daily trading volume, of 220,625 shares, the days-to-cover ratio is currently 0.3 days. Currently, 0.2% of the company’s shares are sold short.

Hedge Funds Weigh In On China SXT Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of SXTC. XTX Topco Ltd purchased a new stake in shares of China SXT Pharmaceuticals during the fourth quarter valued at approximately $36,000. Virtu Financial LLC boosted its stake in shares of China SXT Pharmaceuticals by 107.5% in the third quarter. Virtu Financial LLC now owns 28,983 shares of the company’s stock valued at $46,000 after purchasing an additional 15,013 shares during the period. Finally, Citadel Advisors LLC acquired a new stake in China SXT Pharmaceuticals during the 3rd quarter valued at $78,000. Hedge funds and other institutional investors own 5.02% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of China SXT Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a research note on Friday, June 5th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

China SXT Pharmaceuticals Price Performance

Shares of NASDAQ SXTC traded down $0.19 on Thursday, hitting $2.35. The company had a trading volume of 15,429 shares, compared to its average volume of 191,885. China SXT Pharmaceuticals has a 12-month low of $1.25 and a 12-month high of $1,046.98. The business has a 50 day moving average of $1.89 and a two-hundred day moving average of $41.98.

About China SXT Pharmaceuticals

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.